Literature DB >> 27121524

Adherence to anti-retroviral drugs.

Manas Pratim Roy1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27121524      PMCID: PMC4859135          DOI: 10.4103/0971-5916.180227

Source DB:  PubMed          Journal:  Indian J Med Res        ISSN: 0971-5916            Impact factor:   2.375


× No keyword cloud information.
Sir, The article on adherence of people living with HIV to anti-retroviral therapy (ART) is well-timed and deserves credit for pointing out certain delicate issues1. However, consideration of a few points would have strengthened the study. It is not clear why education, gender, employment status and socio-economic status were not considered for regression. Previous studies from India have found evidences that these factors influence adherence to ART in our set up where drug is provided free of cost but attending ART centres once a month may not be possible for patients challenged with sickness and economic instability234. Authors have mentioned stock-out of ART as one of the reasons for poor adherence. From programmatic point of view, it was important to know the extent of the problem as free availability of ART is a major recognized reason for adherence4. In addition, it is difficult to draw any conclusion from the relationship between duration of ART and poor adherence. Those who are new to ART, adherence may be an issue due to side effects. It improves when they are getting habituated (>7 months duration), as evident from the study. However, the reason for drop in adherence once they complete one year of treatment, is not clear. It might be simply due to sub-optimal grouping of patients, based on duration of ART. A study from Bengaluru has reported that the new patients (on ART for less than 6 months) or those who are taking drugs for more than 10 years are more likely to miss medication5. Similarly, in the present study, regrouping of patients with a longer interval (e.g. <1 year, 1-3 years or so) would have yielded meaningful conclusion about effect of duration of ART on adherence. In brief, further analysis is warranted in patients taking ART for more than one year.
  5 in total

1.  Adherence to antiretroviral therapy & its determinants amongst HIV patients in India.

Authors:  A Sarna; S Pujari; A K Sengar; R Garg; I Gupta; J van Dam
Journal:  Indian J Med Res       Date:  2008-01       Impact factor: 2.375

Review 2.  Optimizing adherence to antiretroviral therapy.

Authors:  Seema Sahay; K Srikanth Reddy; Sampada Dhayarkar
Journal:  Indian J Med Res       Date:  2011-12       Impact factor: 2.375

3.  Adherence to anti-retroviral therapy among HIV patients in Bangalore, India.

Authors:  Mary B Cauldbeck; Catherine O'Connor; Mortimer B O'Connor; Jean A Saunders; Bhimasena Rao; V G Mallesh; Nagendrappa Kotehalappa Praveen Kumar; Gurushanthappa Mamtha; Claire McGoldrick; Robert Bs Laing; Kadappa Shivappa Satish
Journal:  AIDS Res Ther       Date:  2009-04-28       Impact factor: 2.250

4.  Adherence to antiretroviral therapy in India: a systematic review and meta-analysis.

Authors:  Rahul Mhaskar; Vaibhav Alandikar; Patricia Emmanuel; Benjamin Djulbegovic; Sangita Patel; Atul Patel; Eknath Naik; Shyam Mohapatra; Ambuj Kumar
Journal:  Indian J Community Med       Date:  2013-04

5.  Adherence to anti-retroviral therapy & factors associated with it: A community based cross-sectional study from West Bengal, India.

Authors:  Sobha Pahari; Sitesh Roy; Alpana Mandal; Shymal Kuila; Samiran Panda
Journal:  Indian J Med Res       Date:  2015-09       Impact factor: 2.375

  5 in total
  2 in total

1.  Exploring the barriers to the antiretroviral therapy adherence among people living with HIV in Bangladesh: A qualitative approach.

Authors:  Fariha Hossain; Mahmudul Hasan; Nilufar Begum; Devi Mohan; Sharuna Verghis; Nowrozy Kamar Jahan
Journal:  PLoS One       Date:  2022-10-21       Impact factor: 3.752

2.  Authors' response.

Authors:  S Pahari; S Roy; A Mandal; S Kuila; S Panda
Journal:  Indian J Med Res       Date:  2016-02       Impact factor: 2.375

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.